TS-075260 — Problem Type 2 diabetes and related metabolic disorders affect hundreds of millions of patients and are frequently accompanied by chronic inflammation, which accelerates disease progression and complications. Existing antidiabetic therapies often fail to adequately address inflammatory pathways and…

TS-075258 — PROBLEM Chronic heart failure following myocardial infarction (MI) afflicts ~6.7 million US adults and is driven by maladaptive immune activation, particularly persistent activation and proliferation of CD4+ T cells. Existing anti-inflammatory and immunomodulatory approaches have largely failed to …

TS-075247 — PROBLEM Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, affecting women at a 9:1 rate as compared to men. The etiology of SLE is complex and incompletely understood; however, the susceptibility of women during the years in which estrogen levels ar…

TS-075245 — Problem Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy Solution Applications Advantages Seeking opp…

TS-075242 — THE PROBLEM Although immune checkpoint blockade (ICB) has emerged as promising cancer immunotherapy, many tumors fail to respond to ICB. This failed response is often driven by the activation of TGF-β1 in the tumor microenvironment (TME), which induces regulatory T cells and inhibits the funct…

TS-075191 — PROBLEM Cancer immunotherapies (e.g. ICB, CAR-T cells, and conventional bispecific T cell engagers) have transformed treatment of hematological and solid malignancies; however, their impact is limited by several factors including insufficient durability of therapeutic activity, tumor heterogeneity,…

TS-075186 — PROBLEM Exhausted CD8 T cells significantly limit the effectiveness of immunotherapies and cell therapies in cancer and chronic viral infections. Persistent antigen exposure drives durable epigenetic reprogramming that locks T cells into a dysfunctional state, silencing effector and memory-associat…

TS-075175 — Problem Idiopathic pulmonary fibrosis (IPF) is a chronic disease where activated fibroblasts mediate the abnormal accumulation of extracellular matrix (ECM) in the lung interstitial space, leading to progressive impairment of pulmonary function. Current IPF therapies are associated with significant…

TS-075167 — PROBLEM CAR T-cell therapy against CD19 has become the standard of care for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), the most common kind of lymphoma. Recent studies have identified clinical risk factors for prediction of CAR T therapy failure; however, these risk factors are inconsis…

TS-075163 — THE PROBLEM High-grade gliomas, including glioblastoma multiforme (GBM), are the most common primary central nervous system tumors with a high recurrence rate and extremely poor overall survival with a 5-year survival rate of approximately 5%. Despite success of CAR-T therapy in treating blood canc…